๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
China National Study of Adrenal Venous Sampling
NCT06192238Hyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
1,500
Beijing, Chongqing, Xiamen, Lanzhou, Foshan, Guangzhou, Shenzhen, Nanning
2024-01-01
Recruiting
Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer
NCT06775977Bladder Cancer, Staging, Contrast Enhanced Ultrasound
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
480
Guangzhou
2024-01-01
Recruiting
Electro-acupuncture to Treat Disorder of Consciousness
NCT06268236Disorder of Consciousness, Electroacupuncture
The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Not applicable
50
Guangzhou
2024-01-01
Recruiting
The Cold Ischemia Robot-assisted Partial Nephrectomy
NCT07326280Renal Cell Carcinoma, Renal Function Abnormal
Sun Yat-sen University
Not applicable
310
Guangzhou
2024-01-01
Recruiting
Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study
NCT07054229Microwave Ablation, Contrast-enhanced Ultrasound, Genetic and Molecular Diagnostics, Papillary Thyroid Microcarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
480
Guangzhou
2024-01-01
Recruiting
Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale
NCT07051083Bladder Cancer, Staging, Deep Learning, Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
480
Guangzhou
2024-01-01
Recruiting
SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
NCT06173947End Stage Liver Disease, Jaundice, Liver Dysfunction, Portal Hypertension
Nanfang Hospital, Southern Medical University
Observational
411
Guangzhou
2024-01-01
Active, closed
Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: An MRI Study
NCT06881225Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
300
Guangzhou
2024-01-01
Recruiting
Dynamic Monitoring of ctDNA and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery
NCT06420427cfHPV DNA in Plasma of Cervical Cancer Patients
The Third Affiliated Hospital of Guangzhou Medical University
Observational
150
Guangzhou
2024-01-01
Recruiting
Exploring the Diagnostic Performance of Dynamic Chest Radiology in Chronic Obstructive Pulmonary Disease
NCT06653413Chronic Obstructive Pulmonary Disease (COPD)
Nanfang Hospital, Southern Medical University
Observational
2,500
Guangzhou
2024-01-01
Recruiting
Early Warning and Intervention Mechanism of Foot Health Risk in Children and Adolescents
NCT06581978Flexible Flatfoot
Nanfang Hospital, Southern Medical University
Not applicable
120
Guangzhou
2024-01-01
Not yet open
Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus
NCT06085378Acute Ischemic Stroke, Type 2 Diabetes
First Affiliated Hospital, Sun Yat-Sen University
Not applicable
630
Guangzhou
2024-01-01
Recruiting
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
NCT06843707Lung Cancer, Lung, Lung Cancer (NSCLC), Metabolomics
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2024-01-01
Active, closed
Rheumatoid Arthritis Real-world Cohort Study in China (ReALSA)
NCT06233929Rheumatoid Arthritis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
2,000
Guangzhou
2024-01-01
Recruiting
TEER for Severe DMR of Low to Intermediate Surgery Risk
NCT06162780Mitral Regurgitation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
160
Guangzhou
2024-01-01
Not yet open
Vitamin D Levels in Neonatal Umbilical Cord Blood: Factors and Prognostic Analysis
NCT06111066Vitamin d Deficiency
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
186
Guangzhou
2024-01-01
By invitation
Fetal Magnetic Resonance Imaging: Z-score Reference Ranges for a Large Patient Population in Normal Neuroimaging Measurement
NCT07004283Fetal Growth Retardation, Fetal Neurodevelopmental Disorder
Guangzhou Women and Children's Medical Center
Observational
800
Guangzhou
2024-01-01
Recruiting
Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease
NCT06780683Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Xiang Gao
Observational
174
Guangzhou, Meizhou, Shenzhen, Liuzhou, Nanning
2024-01-01
Recruiting
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
NCT06221683AML, Childhood, Acute Myeloid Leukemia
Children's Hospital of Soochow University
Phase 2
500
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-01-01
Recruiting
Ultrasound-Guided Curved Needle Thread Carpal Tunnel Release: Efficacy and Safety of a Single-Center, Single-Arm Clinical Trial
NCT06440070Carpal Tunnel Syndrome
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
69
Guangzhou
2024-01-01
Recruiting
Multi-modality Echocardiography for Cardiac Assessment in Primary Electrical Disease
NCT06172842Multi-modality Echocardiography, Primary Electrical Disease
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
30
Guangzhou
2024-01
Recruiting
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
NCT06197139Advanced Solid Tumor
Xinlu Wang
Phase 1
20
Guangzhou
2024-01
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
Merck Sharp & Dohme LLC
Phase 3
1,310
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-12-31
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
Merck Sharp & Dohme LLC
Phase 3
340
Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou
2023-12-31
Recruiting
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
NCT05457829Rhabdomyosarcoma, Child
Sun Yat-sen University
Phase 2
88
Guangzhou
2023-12-30
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Shanghai, Hangzhou
2023-12-29
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
2023-12-29
Recruiting
a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection๏ผˆPROFOUND๏ผ‰
NCT06217900Cancer
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
Sanofi
Phase 3
943
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Jiazhuang
2023-12-27
Recruiting
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
NCT06201065Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3
200
Guangzhou
2023-12-26
Recruiting
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
NCT06155084Metastatic Castration-resistant Prostate Cancer
Hinova Pharmaceuticals Inc.
Phase 1/2
84
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2023-12-26
Recruiting
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
NCT06094556Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
240
Guangzhou
2023-12-25
Recruiting
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
NCT06139575Prostate Cancer
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou
2023-12-21
Recruiting
PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study
NCT06336239Cardiovascular Disease, Type 2 Diabetes Mellitus
Beijing Anzhen Hospital
Observational
3,000
Beijing, Chongqing, Haidong, Guangzhou, Shijiazhuang, Luoyang, Yongcheng, Zhengzhou
2023-12-21
Active, closed
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naรฏve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 3
190
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-12-21
By invitation
The Construction and Effect Verification of a Deep Learning-based Automated Semantic Segmentation Model for Medical Imaging
NCT06864702Artificial Intelligence (AI), Deep Learning, Laparoscopic Surgery
Zhujiang Hospital
Not applicable
220
Guangzhou
2023-12-20
Recruiting
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
NCT06190301Primary Ocular Adnexal MALT Lymphoma
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
108
Guangzhou
2023-12-20
Recruiting
A Study of TAVO412 in Patients with Cancer (TAVO412)
NCT06761651Cancer
Tavotek Biotherapeutics
Phase 1
50
Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Jinan
2023-12-20
Active, closed
Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs
NCT06175637Neurofibroma, Plexiform
AstraZeneca
Observational
409
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-12-20
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
400
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Zhengzhou, Wuhan
2023-12-20
Recruiting
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
NCT06167694Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
146
Beijing, Guangzhou
2023-12-20
Recruiting
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
NCT06082102Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
324
Bengbu, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Dalian
2023-12-19
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing
2023-12-18
Recruiting
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06007729Head and Neck Squamous Cell Carcinoma
Hansoh BioMedical R&D Company
Phase 2
170
Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou
2023-12-18
Recruiting
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
NCT06249308Ovarian Cancer
Fudan University
Observational
168
Guangzhou, Shenyang, Shanghai
2023-12-18
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Hansoh BioMedical R&D Company
Phase 2
460
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-12-18
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin
2023-12-15
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
NCT06433869Malignant Ascites
Sun Yat-sen University
Phase 2
60
Guangzhou
2023-12-14
Active, closed
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06082635Non Small Cell Lung Cancer
Shenzhen TargetRx Co., Ltd.
Phase 3
321
Guangzhou
2023-12-14
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou
2023-12-13
Recruiting
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
NCT06088030Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations
Yang Li
Phase 2
50
Guangzhou
2023-12-13
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Guiyang, Haikou
2023-12-13
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
Sanofi
Observational
100
Guangzhou, Xi'an, Jinan, Hangzhou, Wenzhou, Beijing, Shanghai, Shenzhen
2023-12-12
Recruiting
Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye
NCT07634913Artifical Intelligence, Cataract, Pterygium, Keratopathy
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
3,000
Guangzhou
2023-12-12
Recruiting
HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
NCT05861895Solid Tumors, Adult
HighField Biopharmaceuticals Corporation
Phase 1
84
Guangzhou
2023-12-12
Recruiting
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
NCT06122831Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
92
Guangzhou, Nanning, Cangzhou, Chengde, Tangshan, Xingtai, Harbin, Zhengzhou
2023-12-12
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
PostoperAtive Neurocognitive Dysfunction After Major AbdomiNal Surgery (PANDAMAN)
NCT06182215Elective Major Abdominal Surgery
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
500
Guangzhou
2023-12-11
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche
Phase 3
1,050
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2023-12-11
Recruiting
A Phase โ…ก Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
NCT06177925Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms
Nanfang Hospital, Southern Medical University
Phase 2
62
Guangzhou
2023-12-10
Recruiting
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
NCT06157827Advanced Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
178
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang
2023-12-08
Recruiting
SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
NCT06219980SBRT
Sun Yat-sen University
Phase 2
25
Guangzhou
2023-12-07
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
Novartis Pharmaceuticals
Phase 3
362
Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, รœrรผmqi
2023-12-07
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
AstraZeneca
Phase 1/2
226
Beijing, Changsha, Guangzhou, Shenyang
2023-12-05
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Deyang, Fuzhou, Guangzhou, Guiyang
2023-12-04
Active, closed
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
NCT06118333Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
386
Guangzhou
2023-12-04
Recruiting
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
NCT05998759Connective Tissue Diseases, Thrombocytopenia
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
400
Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha
2023-12-01
Active, closed
Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope
NCT06710873CIED Infection, TYRX Absorbable Antibacterial Envelope
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
50
Guangzhou
2023-12-01
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Recruiting
Biometric Changes After Intervention of Anterior Chamber Angle : an Observational Study
NCT06492538Angle-closure Glaucoma, Minimally Invasive Glaucoma Surgery, Goniosynechialysis, Goniotomy
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
300
Guangzhou
2023-12-01
Recruiting
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
NCT07353216Multiple Sclerosis
Third Affiliated Hospital, Sun Yat-Sen University
Observational
80
Guangzhou
2023-12-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF
NCT06161987Acute Decompensated Heart Failure
Guangdong Provincial People's Hospital
Not applicable
140
Guangzhou
2023-12-01
By invitation
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
NCT06281964Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd.
Phase 3
327
Guangzhou
2023-12-01
Active, closed
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
NCT05975307Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy
Sun Yat-sen University
Phase 2
71
Guangzhou
2023-12-01
Active, closed
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
NCT06194825Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Haโ€™erbin, Jinan
2023-12-01
Recruiting
POEM-F for Achalasia International Study
NCT06042127Achalasia
Chinese University of Hong Kong
Not applicable
81
Guangzhou
2023-12-01
Recruiting
Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures
NCT06379243Osteoporosis Fracture, Osteoporosis Vertebral, Compression Fracture, Perform PVP / PKP Treatment
The Seventh Affiliated Hospital of Sun Yat-sen University
Not applicable
560
Guangzhou
2023-12-01
Recruiting
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
NCT06876688CNS Lymphoma
Ruijin Hospital
Phase 2
30
Beijing, Guangzhou, Henan, Shanghai, Wuhan
2023-11-30
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Recruiting
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT06155383Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Recruiting
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV
Women's Hospital School Of Medicine Zhejiang University
Phase 3
538
Guangzhou, Ji'nan, Hangzhou, Ningbo, Wenzhou
2023-11-27
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Active, closed
Guangzhou Preterm and Term Birth Cohort Study
NCT07756177Preterm Birth, Neurodevelopmental Disorders, Overweight, Obesity
Sun Yat-sen University
Observational
200
Guangzhou
2023-11-21
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Guangzhou, Jinan, Shanghai
2023-11-20
Recruiting
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
NCT06157060Hepatocellular Carcinoma Resectable
Zhujiang Hospital
Observational
255
Foshan, Guangzhou, Shaoguan
2023-11-20
Active, closed
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
NCT06057571Cholangiocarcinoma Metastatic
TransThera Sciences (Nanjing), Inc.
Phase 2
50
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2023-11-17
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Recruiting
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behรงet's Disease
NCT06145893Behรงet's Disease
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Rows per page Showing 2101–2200 of 3318
Previous 20 21 22 23 24 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=22

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.